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WHAT THIS PAPER ADDS?
 This study identiﬁes research gaps in economic evidence in the context of carotid artery stenosis diagnosis and treatment. Settings
inwhich the most cost-effective treatment strategy is still unknownwere identiﬁed. We recommend ﬁlling these gaps in economic
evidence. In the long run, this may lead to the more efﬁcient use of available resources.a r t i c l e i n f o
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The objective of this article is to assess the availability and validity of economic evaluations of carotid
artery stenosis (CS) diagnosis and treatment.
Design: Systematic review of economic evaluations of the diagnosis and treatment of CS.
Methods: Systematic review of full economic evaluations published in Medline and Google Scholar up
until 28 February 2012. Based on economic checklists (Evers and Philips), the identiﬁed studies were
classiﬁed as high, medium, or low quality.
Results: Twenty-three evaluations were identiﬁed. The study quality ranged from 26% to 84% of all
achievable points (Evers). Seven studies were of high, eight of medium and eight of low quality. No
comparison was made between carotid angioplasty and stenting (CAS) and best medical treatment
(BMT). For subjects with severe stenosis, comparisons of carotid endarterectomy (CEA) and BMT were
also missing. Three of ﬁve studies dealing with pre-operative imaging found that duplex Doppler
ultrasound (US) was cost-effective compared with carotid angiogram (AG).
Conclusions: There is a huge lack of high-quality studies and of studies that conﬁrm published results.
Also, for a given study quality, the most cost-effective treatment strategy is still unknown in some cases
(‘CAS’ vs. ‘BMT’, ‘US combined with magnetic resonance angiography supplemented with AG’ vs. ‘US
combined with computer tomography angiography’).
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Carotid artery stenosis (CS) is an important cause of stroke; 20%
of all ischaemic strokes are caused by severe carotid stenosis.1
There are several methods for the detection and treatment of CS.
These include carotid endarterectomy (CEA), carotid angioplasty
and stenting (CAS) and multiple imaging technologies.
Although new and costly methods for the detection and treat-
ment of CS are being developed, it is unclear whether the additional
costs are justiﬁed in terms of both effectiveness and cost-x: þ49 89 3187 3375.
enchen.de (B. Stollenwerk).
lit ﬁrst authorship).
ciety for Vascular Surgery. Publisheeffectiveness.2,3 In particular, the development of imaging strate-
gies has led to a huge cost increase in the past two decades.2
Nowadays, economic evaluations are frequently conducted to
assess the economic impact of health interventions. A full economic
evaluation is deﬁned as an analysis that, ﬁrst, compares at least two
alternative strategies and, second, considers both costs and
consequences.3 The main types of full economic evaluations are
cost-effectiveness, costeutility and costebeneﬁt analysis. Further-
more, there is cost-minimisation analysis, based on the precondi-
tion that the considered treatment strategies do not differ with
respect to the health outcome.4
Furthermore, economic evaluations are performed from
a particular perspective, most commonly the societal perspective.d by Elsevier Ltd. All rights reserved.
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tions and original data analyses (ODAs). ODAs require fewer
assumptions but are restricted to the follow-up period. However,
models usually combine information from multiple sources.
Several checklists exist to assess the quality of economic anal-
yses.4e7 These assess, for example, whether the model structure is
suitable, whether data sources are appropriate and whether the
uncertainty of the results has been considered appropriately.
A simple way of assessing parameter uncertainty is determin-
istic sensitivity analysis (DSA). In DSA, results are re-calculated
based on explicitly speciﬁed parameters. To assess the overall
effect of parameter uncertainty, probabilistic sensitivity analysis
(PSA) has been developed. In PSA, all uncertain parameters are
sampled simultaneously from distributions that are supposed to
represent the true parameter uncertainty. This results in a proba-
bility distribution of the model outcomes.
Recent developments in health economic evaluation include
displaying results as cost-effectiveness acceptability curves,
because conﬁdence intervals for incremental cost-effectiveness
ratios are often not suitable.8 Furthermore, there has been
research in quality-of-life estimation, such as developing more
robust value sets and the validation of existing ones.9e11 Common
instruments to measure quality of life are the ‘EuroQol e 5
Dimensions’ (EQe5D), the Health Utilities Index (HUI) and the 36-
item short-form health survey (SF-36).12e14 There is also growing
use of Bayesian methods8 research into how to choose appropriate
distributions for PSA,15 as well as applications of the ANCOVA
approach to assess the impact of single-model parameters.8,16
The objectives of this study are, ﬁrst, to identify the economic
evidence (i.e., the availability and validity of economic evaluations)
for interventions in the prevention, diagnosis and treatment of CS.
Second, we aim to identify settings where economic evidence is
lacking in making a decision about which strategy should be per-
formed when considering both cost and consequences.
Materials and Methods
We performed a systematic review on the health economic
evidence of CS prevention, diagnosis and treatment. Only full
economic evaluations were considered. We restricted our search to
the search engines PubMed and Google Scholar, as these search
engines cover a wide range of literature relevant to the scientiﬁc
audience. Based on the search terms ‘carotid artery stenosis’, ‘carotid
angioplasty’, ‘duplex ultrasound’, etc., a search algorithm was built
(for the full research strategy, see Appendix). In addition, we
screened the references of the identiﬁed relevant articles. Two
investigators (AS and MJ) examined the titles and abstracts of the
potentially eligible articles. Once the articles were chosen, the
inclusion of the articles was discussed in cases of differences of
opinion (MJ, AS and BS). In cases of queries, discussions were carried
out among the reviewers (AS, MJ and BS). The systematic reviewwas
performedon February28, 2012 (last update). Adetailed report of the
methodological assessment is available from the authors on request.
Only original papers were included; comments on papers,
systematic reviews, meta-analysis and protocols were excluded.
Furthermore, the articles had to be abstracted in English.
We classiﬁed the studies into cost-minimisation analyses, cost-
effectiveness analyses, costeutility analyses and costebeneﬁt
analyses.4 Articles that did not explicitly state the perspective
were classiﬁed according to the reported costs. All included studies
were assessed according to Evers’ checklist;17 all modelling studies
were also assessed according to Philips’ checklist.6
All papers were furthermore classiﬁed as high, medium or low
quality, depending on their quality rating and on the clinical
evidence. To be rated of high quality, the clinical evidence of themain health effect needed to be based on at least one randomised
controlled trial (RCT) or on a meta-analysis of RCTs of sufﬁcient
quality. Furthermore, at least 50% of all Evers’ and 50% of all Philips’
criteria needed to be fulﬁlled, and ﬁnally, the health outcome
needed to be rated as appropriate. If the health outcome used or the
clinical evidencewas rated as inappropriate, or if less than 40% of all
Evers’ or all Philips’ criteria were fulﬁlled, studies were rated as low
quality. All studies that met the minimum requirements, but did
not meet all the criteria to be rated as high, were classiﬁed as
medium quality.
To interpret the overall strength of the health economic
evidence, we used the following scheme. Strong evidence required
two or more studies of high quality, moderately strong evidence
required two ormore studies of medium or high quality and limited
evidence required at least one study of medium or high quality.
Finally, insufﬁcient evidence represents the situation in which
there are no studies available, when all available studies have low
quality or when the available studies of the highest quality provide
contradictory conclusions. To judge whether studies provide
contradictory conclusions, we considered the conclusions drawn
within the study.
Results
Initially, 570 studies from PubMed and 6020 studies from
Google Scholar were identiﬁed by the search algorithm (Fig. 1).
Only 49 studies were assessed as a full text after removing the
duplicates and screening the records. From these 49 studies, 26
studies were excluded (see Fig. 1), mainly because they were not
a full economic evaluation (19 studies) or did not focus on CS (4
studies). Altogether, 23 studies were included. More than two-
thirds of the studies (17 studies)18e34 referred to the United
States of America. Six studies referred to European countries,
mostly the Netherlands (three studies).35e37
Most evaluations (17 studies) were costeutility analyses,
20e23,25e29,31e38 two were cost-effectiveness analyses39,40 and four
studies were cost-minimisation analyses.18,19,24,30 With respect to
the model type, 14 studies used Markovmodels,20,22,25e28,31e38 two
studies used unclassiﬁed decision-analytic models,21,23 and seven
studies used ODAs.18,19,24,29,30,39,40 Two of the ODAs were rando-
mised controlled trials.29,39 Almost all the models (14 of 16 studies)
used the lifetime time horizon.20e22,25e28,31e34,36e38 In the
remaining models, the authors chose 10- and 20-year time hori-
zons.23,35 These two models used quality-adjusted life years
(QALYs) as a health outcome. The time horizon used in the ODAs
varied between the hospital stay,24,40 30 days,24,30,39 3 months18
and 1 year.29
Regarding uncertainty assessment, we found 11 models that
performed DSA,22,25e27,31,33,35,36,41 four models that performed
PSA21,38 and three models20,23,28 that performed structural sensi-
tivity analysis (SSA). A total of 15 studies explicitly reported the
study perspective. Of these, 1118e20,23,24,29,31e34,39 studies chose the
third-party payer perspective, and the remaining four21,25,37,38
chose the societal perspective. The remaining studies were classi-
ﬁed into four studies with a societal perspective22,27,35,40 and four
studies with a third-party payer perspective.26,28,30,36
The overall quality assessment yielded seven studies of high,
eight of medium and eight of low quality (Tables 1e3). Methodo-
logical quality according to Evers’ list (all economic evaluations)
ranged from 26% to 84% with an average of 61% (Tables 1e3). The
model quality according to Philips’ list ranged from 31% to 74% of all
achievable points (average 52%) (Table 4). Although structural
aspects have been considered best (on average 68%), data identi-
ﬁcation and synthesis ranked second (49%) and uncertainty
assessment and consistency ranked lowest (36%) (Table 4).
After duplicates removed: 6,405 
Records screened: 6,405 
Google Scholar: 6,020 Pubmed: 570 
Full text articles assessed for  
eligibility: 49 
No full economic evaluation: 19 
No focus on carotid artery stenosis: 4 
No original research: 1 
Non-English publication: 1 
Conference abstract: 1 
Studies included in the qualitative 
synthesis: 23 
Records excluded: 6,356 
Cost-utility: (17) 
Bluth et al. 
Burnett et al. 
Cronenwett et al 
Mahoney et al. 
Derdeyn et al. 
Henriksson et al. 
Janssen et al. 
Kent et al. 
Kilaru et al. 
Kuntz et al. 
Patel et al. 
Patel et al. 
Tholen et al. 
Yin et al. 
Young et al. 
Lee et al. 
Post et al. 
 
Cost-effectiveness: (2) 
Gomes et. al. 
Gürer et al. 
Cost-minimization: (4) 
Back et al. 
Ballard et al. 
Garrad et al. 
Park et al. 
Figure 1. Schematic representation of selection process of studies examining the cost of various interventions in carotid artery stenosis.
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Concerning the economic evaluation of carotid stenosis treat-
ment, nine studies were identiﬁed22,26,27,29e31,34,35,38 (Tables 1 and
5). Besides the available treatment options (CEA, CAS and best
medical treatment (BMT)), the studies also differed with respect to
the target population (symptomatic vs. asymptomatic patients,
moderate vs. severe stenosis, high risk groups). Strong evidence
was found only for two settings: ﬁrst, symptomatic patients with
severe stenosis treatedwith CEAvs. CAS and, second, asymptomatic
patients with moderate stenosis treated with CEA vs. BMT. For the
remaining comparisons, either only one high-quality study was
available or economic evaluations were not available at all (Table 5).
When comparing CEA vs. CAS in ‘asymptomatic patients with
severe stenosis’ and in ‘symptomatic patients with moderate
stenosis,’ we considered differences in the target population (high
risk vs. average risk) when classifying the results, as they yielded
different conclusions.
All studies comparing CEA with BMT22,27,31,38 basically agreed
that CEA is cost-effective for patients with moderate stenosis.
However, three reported a variation in the result with respect to
age.22,31,38 No study was found comparing CAS with BMT (insufﬁ-
cient evidence). Comparisons of CEA and BMT are lacking for
patients with severe stenosis (insufﬁcient evidence). However,
there is moderate evidence comparing CEA with BMT in symp-
tomatic patients with moderate stenosis and strong evidencecomparing CEAwith BMT in asymptomatic patients with moderate
stenosis. In these cases, CEA is regarded as cost-effective compared
with BMT.
Although CEA was compared with both CAS and BMT, no
comparisons were made between CAS and BMT (insufﬁcient
evidence). Furthermore, no comparisons were made between CEA
and CAS for asymptomatic moderate stenosis patients.
Economic evaluation of CEA supporting procedures
CEA is the standard treatment for carotid stenosis and, like other
surgeries, it is accompanied by different procedures and investi-
gations. Ten studies are related to such procedures and investiga-
tions (Table 2). They were divided into three groups: studies
comparing pre-operative investigation; studies dealing with intra-
operative procedures; and studies on post-operative ultrasound
surveillance.
The standard pre-operative imaging is the carotid angiogram
(AG), and there were ﬁve studies that compared potential alter-
natives with AG.18,19,24,25,37 Potential comparators were ‘US’,‘AG’,
‘MRA’, ‘computed tomography angiography’ (CTA), and the
combined strategies ‘US þ CTA’,‘US þ MRA’ and ‘US þ MRA sup-
plemented with AG’. There was no strong evidence for any of the
pairwise comparisons, as the evidence in none of the studies was
based on RCTs. Moderate evidencewas available for the comparison
of ‘MRA’ vs. ‘US’ (two studies of medium quality concluded that
Table 1
Economic evaluation of carotid stenosis treatment.
Authors Year Country Evaluation
type
Model
type
Perspectives Time
horizon
Treatment Health outcome Cost/cost-effectiveness
(main result)
Major data source Assessment of
health utilities
Males
(%)
Age
mean
range
(years)
Evers’ list
score (%)
Evidence
level
Mahoney
et al.
2011 USA CUA ODA, RCT Third party
payer
1 year CAS vs. CEA QoL, life
expectancy,
QALY
ICER: $6555/QALY
gained for stenting
SAPPHIRE trial EQe5D
(Dolan’s value set),
time trade-off
68 72 79 High
Young
et al.
2010 USA CUA MM Third party
payer
Lifetime CAS vs. CEA POR, QALY,
stroke,
death, MI
CEA dominant Gurm et al.:
meta-analysis,
Luebeke et al.:
meta-analysis,
SPACE trial, EVA-3S
trial, SAPPHIRE trial,
NASCET, ECST, ACST
Systematic review
of utility values
(based on EuroQoL)
NS 70 63 High
Janssen
et al.
2008 NL CUA MM Societal 10 years CAS vs. CEA Major stroke
rates, long-term
survival, QALY
CEA dominant ECST trial, Ederle et al.:
Cochrane Review,
Wohley et al.: Review
Systematic
review of utility
values (no unique
method)
NS NS 53 Medium
Park et al. 2006 USA CM ODA, CT Third party
payer
30 days CAS vs. CEA Perioperative
mortality, MI
stroke, and death
CEA dominant ODA Not applicable 53 71 63 Low
Kilaru et al. 2003 USA CUA MM Third party
payer
Lifetime CAS vs. CEA QALY, major and
minor stroke
CEA dominant NASCET Rating scale NS 70
(50e90)
58 High
Henriksson
et al.
2008 SE CUA MM Societal Lifetime CEA vs. BMT QALY ICER: V34,557/QALY
gained for CEA
ACST EQe5D, HUI 2&3,
time trade-off
NS 70 68 High
Patel et al. 1999 USA CUA MM Third party
payer
Lifetime CEA vs. BMT QALY, POR of
stroke
or death,
medical
and surgical
stroke risk
ICER: $4462/QALY
gained for CEA
NASCET Rating scale NS 66
(60e90)
84 High
Cronenwett
et al.
1997 USA CUA MM Societal Lifetime CEA vs. BMT Major stroke,
minor
stroke, death,
QALY
ICER: $8000/QALY
gained for CEA
ACAS, NASCET,
ECST, and Veterans
Administrative
Cooperative Study
Assumptions
based on
previous models
66 67 84 High
Kuntz and
Kent
1996 USA CUA MM Societal Lifetime CEA vs. BMT QALY,
morbidity,
mortality
ICER: $4100/QALY
gained for CEA
NASCET, ACAS Assumptions 100 65 58 Medium
ACAS: Asymptomatic Carotid Atherosclerosis Study; ACST: Asymptomatic Carotid Surgery Trial; BMT: best medical therapy; CAS: carotid angioplasty and stents; CEA: carotid endarterectomy; CM: cost minimization; CT:
controlled trial; CUA: costeutility analysis; ECST: European Carotid Surgery Trial; EQe5D: EuroQol e 5 Dimensions; EuroQoL: European Quality of Life Scale; EVA-3S trial: The Endarterectomy vs. Angioplasty in Patients with
Symptomatic Severe Carotid Stenosis Trial; HUI: Health Utilities Index; ICER: incremental cost-effectiveness ratio; MI: myocardial infarction; MM: Markov model; NASCET: The North American Symptomatic Carotid Endar-
terectomy Trial; NL: Netherlands; NS: not stated; ODA: original data analysis; POR: perioperative rate; QALE: quality-adjusted life expectancy; QALY: quality-adjusted lifeeyear; QoL: quality of life; RCT: randomized controlled
trial; SAPPHIRE: Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Trial; SE: Sweden; SPACE: Stent-Protected Angioplasty vs. Carotid Endarterectomy Trial; USA: United States of
America.
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Table 2
Economic evaluation of CEA supporting procedures.
Authors Year Country Evaluation
type
Model type Perspectives Time
horizon
Treatment Health outcome Cost/cost-effectiveness
(main result)
Major data
source
Assessment of
health utilities
Males
(%)
Age
mean range
(years)
Evers’ list
score (%)
Evidence
level
Tholen
et al.
2010 NL CUA MM Societal Lifetime US vs. MRA vs. CTA QALY,
long-term events,
net health beneﬁts
ICER: V71,419/QALY
gained for CTA
NASCET Previous models,
based on EQe5D,
SF-36, QWB, etc.
58 62 79 Medium
Gomes
et al.
2010 UK CE ODA, RCT Third party
payer
30 days LA vs. GA Stroke, morbidity,
mortality rates, MI
LA dominant GALA Not applicable 70 NS 58 High
Burnett
et al.
2005 USA CUA DAM Societal Lifetime US vs. completion
AG. Other
intervention:
US vs. none
Perioperative
stroke, mortality, QoL
US dominant Systematic
review
Not applicable NS NS 42 Low
Gürer
et al.
2003 TR CE ODA,
obser-vational
study
Societal Hospital
stay
LA vs. GA Mortality,
morbidity rates, stroke
LA dominant ODA Not applicable 70 65 26 Low
Post et al. 2002 NL CUA MM Third party
payer
Lifetime US surveillance vs.
symptom-guided
surveillance
QALY, probability
of stroke, minor
disability, major
disability, death
Symptom-guided
surveillance is
dominant
NASCET Time trade-off 70 66 84 Medium
Patel
et al.
1998 USA CUA MM Third party
payer
Lifetime Post-operative
surveillance
QALY, stroke, DR ICER: $126,950/QALY
gained for none
ACAS Rating scale 100 65 68 Medium
Garrard
et al.
1997 USA CM ODA, CT Third party
payer
Hospital
stay
US vs. AG Operative results,
complications
US dominant ODA Not applicable NS 68
(45e92)
58 Low
Back
et al.
1997 USA CM ODA, CT Third party
payer
3 months CEA pathway vs.
pre-CEA pathway
MR, complication,
stroke
CEA pathway
dominant
ODA Not applicable NS 69
(50e90)
68 Low
Ballard
et al.
1997 USA CM ODA, case
series analysis
Third party
payer
30 days US vs. AG Stroke, DR US dominant ODA Not applicable 53 74
(43e91)
53 Low
Kent
et al.
1995 USA CUA MM Societal Lifetime US vs. MRA vs.
AG vs. combination
(US þ MRA)
Mortality, morbidity ICER: $22,400/QALY
gained for
combination
(US þ MRA)
NASCET Assumptions 58 70
(48e87)
64 Medium
ACAS: Asymptomatic Carotid Atherosclerosis Study; AG: angiography; CE: cost-effectiveness; CM: cost minimization; CT: controlled trial; CTA: computer tomographic angiography; CUA: costeutility analysis; DAM: decision-
analytical model; DR: death rate; EQe5D: EuroQol e 5 Dimensions; GA: general anaesthesia; GALA: General Anaesthesia vs. Local Anaesthesia for Carotid Surgery Trial; ICER: incremental cost-effectiveness ratio; LA: local
anaesthesia; MI: myocardial infarction; MM: Markov model; MR: mortality rate; MRA: magnetic resonance angiography; NASCET: The North American Symptomatic Carotid Endarterectomy Trial; NL: Netherlands; NS: not
stated; ODA: original data analysis; QALY: quality-adjusted lifeeyear; QoL: quality of life; QWB: Quality of Well-Being; RCT: randomized controlled trial; SF-36: 36-Item Short-Form Health Survey; TR: Turkey; UK: United
Kingdom; US: ultrasound; USA: United States of America.
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Table 4
Quality assessment for the models with a Philips’ list.
Authors Year Structural
aspect (%)
Data (%) Uncertainty
and
consistency
(%)
No. of
applicable
questions
out of 58
Total
Philips’
list
score (%)
Young et al. 2010 86 70 42 54 70
Tholen et al. 2010 68 65 75 54 69
Henriksson et al. 2008 82 75 58 54 74
Janssen et al. 2008 50 45 33 54 44
Burnett et al. 2005 55 25 25 54 37
Kilaru et al. 2003 64 55 25 54 52
Post et al. 2002 50 50 33 54 46
Bluth et al. 2000 55 5 33 55 31
Patel et al. 1999 77 40 50 54 57
Patel et al. 1998 83 50 17 55 56
Yin and Carpenter 1998 68 57 33 55 56
Lee et al. 1997 77 50 42 54 59
Cronenwett et al. 1997 64 50 42 54 54
Kuntz and Kent 1996 59 40 33 54 46
Derdeyn and
Powers
1996 50 20 25 54 33
Kent et al. 1995 68 25 17 54 41
Max. 86 75 75 74
Min. 50 5 17 31
Mean 68 49 36 52
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A.U. Shenoy et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 505e513510MRA was dominant). For the remaining comparisons, there was
limited evidence, as there was one study of medium quality avail-
able for each comparison. Furthermore, several comparisons were
missing (insufﬁcient evidence).
Four studies compared duplex Doppler US with AG.18,19,24,25
Among these, three cost-minimisation analyses (low quality)
from the third-party payer perspective found US to be domi-
nant.18,19,24 However, a study of medium quality from the societal
perspective25 conducted a comparison of four imaging strategies:
‘US’, ‘magnetic resonance angiography’ (MRA), ‘AG’, and a ‘combi-
nation of US and MRA supplemented with AG’. Their conclusion
was that the combination of ‘US andMRA supplementedwith AG’ is
cost-effective compared with the other strategies. The results of
comparisons with other strategies could not be extracted because
they were not reported.25 Another study of medium quality
compared a different set of strategies (US, CTA, MRA), including
combined strategies.37 They concluded that a combination of US
and CTA is the dominant strategy.
Of the studies dealing with intra-operative procedures,18,21,39,40
three studies compared local with general anaesthesia and agreed
that local anaesthesia is cost-effective.18,39,40 However, two of these
studies were of low and one of medium quality, resulting in limited
economic evidence. Burnett et al.21 compared ‘intra-operative US’,
‘completion AG’ and ‘no intra-operative imaging’. However, as this
study was of low quality, these ﬁndings were rated as providing
insufﬁcient evidence.
Finally, with respect to post-operative US surveillance, our review
identiﬁed two studies dealing with post-operative surveillance.32,36
Patel et al. set up a model from the third-party payer perspective
to check the timing of surveillance US or doing no surveillance of the
patient after CEA, and they concluded that no surveillance is cost-
effective.32 Post et al., on the other hand, checked different surveil-
lance strategies, and they concluded that a symptom-guided follow-
up strategy is the most cost-effective.36 Both these studies were of
medium quality, resulting in moderate evidence.
Economic evaluation of screening asymptomatic subjects for carotid
stenosis
A further group of studies evaluates screening programs for
carotid stenosis (Table 3). The main health effect of the screening
Table 5
Health economic evaluation of the treatment of carotid artery stenosis based on subgroup analysis.
Carotid endarterectomy vs. carotid angioplasty
with stenting
Carotid endarterectomy vs. best medical
treatment
Carotid angioplasty with
stenting vs. best medical
treatment
Asymptomatic Symptomatic Asymptomatic Symptomatic Asymptomatic Symptomatic
Moderate stenosis (50%e69%) Park et al., 2006
CEAeDOM (low)
Kuntz and Kent 1996
CEAeCE (medium)
Kuntz and Kent 1996
CEAeCE (medium)
Mahoney et al., 2011
CASeCEa (high)
Cronenwett et al., 1997
CEAeCEb (high)
Patel et al., 1999
CEAeCEb (high)
Young et al., 2010
CEAeDOM (high)
Henriksson et al., 2008
CEAeCEb (high)
Severe stenosis (70%e99%) Park et al., 2006
CEAeDOM (low)
Young et al., 2010
CEAeDOM (high)
Mahoney et al., 2011
CASeCEa (high)
Kilaru et al., 2003
CEAeDOM (high)
Kilaru et al., 2003
CEAeDOM (high)
Janssen et al., 2008
CEAeDOM (medium)
In brackets: study quality; BMT: best medical treatment; CE: cost-effective; CAS: carotid angioplasty with stenting; CEA: carotid endarterectomy; DOM: dominant.
a At high risk group.
b The study result changes according to age.
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of the test. In consequence, all screening studies were classiﬁed as
of medium quality. The studies by Lee et al. and Yin and Carpenter
compared the following strategies: ‘screen with US, conform by AG
and do CEA’, ‘screenwith US and do CEA’ and ‘no screening’.28,33 Lee
et al. concluded that no screening is cost-effective (societal
perspective) compared with the alternatives, whereas Yin and
Carpenter concluded that ‘screening with US, conforming by AG
and doing CEA’ is the most cost-effective strategy (third-party
payer perspective).28,33
Bluth et al. performed a multiple comparison of screening
strategies, including ‘power Doppler imaging’, ‘standard duplex
Doppler’, ‘MRA’ and ‘AG’. They concluded that power Doppler
imaging is cost-effective.20 A further screening study compared US
with and without AG, in high- or low-prevalence populations and
with different timings.23 In their conclusion, screening once in
a high-prevalence asymptomatic group is cost-effective compared
with annual screening.23
Overall, the evaluations of screening yielded contradictory
conclusions. It is unclear whether and how often screening should
be carried out and which screening procedure should be used.
Thus, the evidence with respect to screening for asymptomatic
carotid stenosis patients was judged to be insufﬁcient.
Discussion
We systematically reviewed the literature for economic evalu-
ations of CS treatment, screening and prevention. Although there
are many previous systematic reviews in the context of CS,42e46
only three address economic evaluations.42,44,45
Within our systematic review, we identiﬁed a substantial lack of
economic evidence. Strong evidence was found only for two
settings, and several comparisons were not available at all. In the
context of carotid stenosis treatment, the study quality and the
insufﬁcient number of studies were not the only problems; tomake
a treatment decision based on the published evidence, the
following comparisons were missing: CEA vs. CAS in asymptomatic
patients with moderate stenosis; CEA vs. BMT in symptomatic and
asymptomatic patients with severe stenosis; and CEA vs. BMT in
symptomatic patients with moderate stenosis.
In the context of pre-endarterectomy investigations, none of the
observed comparisons was based on RCTs. Thus, as economic
analyses cannot provide a higher evidence level than the under-
lying clinical studies, there was no study of high quality. However,for a given evidence level, most comparisons have been studied
only once. Moderate evidence was only provided when comparing
MRA vs. US; for the remaining comparisons, there was only limited
evidence (one study of medium quality) or insufﬁcient evidence
(no study). Overall, from the economic point of view, it is impos-
sible to judge sufﬁciently which pre-endarterectomy investigations
should be performed. When ignoring the evidence level of the
single comparisons, one could conclude that either ‘combining US
and MRA supplemented with AG’ or ‘combining US with CTA’ is
preferable; however, a comparison of these two alternatives is also
missing.
In the economic evaluation of carotid intra-endarterectomy
procedures, there was a high proportion of low-quality studies.
Although the existing studies concluded that local anaesthesia was
superior to general anaesthesia, a further high-quality study would
be needed to validate the previous ﬁndings. The study comparing
‘US’ vs. ‘US plus completion AG’ should also be re-evaluated,
following the requirements of Philips’ and Evers’ checklists more
precisely.
According to post-endarterectomy US surveillance, further
studies would be desirable to validate the view that symptom-
guided US surveillance or no US surveillance is the most cost-
effective.
With respect to screening, no RCTs exist that were able to
demonstrate a potential health gain. However, based on prevalence
data, accuracy data from diagnostic tests and the beneﬁt observed
in asymptomatic patients, models found that once-in-a-lifetime
screening in a high-prevalence population is cost-effective. Given
that once-in-a-lifetime screening is cost-effective, it is still unclear
at what age this screening should be performed. To achieve strong
evidence, it would be wise, ﬁrst, to design an ‘optimal’ screening
based on the given data, and then to conduct an RCT to validate the
modelling results.
One limitation of this review is that we may not have identiﬁed
all the relevant studies via our search algorithm. Furthermore,
many different outcome measures, such as QALYs, strokes avoided,
event-free survival, etc., have been used within the economic
evaluations, which complicates comparison. However, even costs
per QALY are limited when comparing results, because the meth-
odology used to derive QALYs may vary substantially. Even if there
were common standards on how to calculate QALYs, further factors
affect the costs per QALY ratio, such as whether unrelated medical
costs are included, for which setting (country, perspective, etc.) the
analysis was performed and other methodological choices.
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a limited methodology of estimating quality of life. As economic
evaluations are often based on secondary data, authors were not
entirely free in choosing the utility measurement methodology.
Sometimes it could not be speciﬁedwhich instrument (e.g., EQe5D,
HUI or SF-36) was used. Neither could it be speciﬁed whether
utilities corresponded to the time-trade-off approach, the standard
gamble or the visual analogue scale. Instead, utility estimates were
blended or even corresponded to an educated guess.
A further limitation is the criteria that we set up to decide
whether there is strong, moderate, limited or insufﬁcient evidence.
The requirement of at least two economic evaluations to conclude
strong or moderate evidence was to guarantee reproducibility.
However, others might be satisﬁed with only one high-quality
study. Furthermore, in some cases, there might be ethical reasons
for not conducting RCTs and, in consequence, strong evidence, as
deﬁned in our study, would never be achieved. The absence of
strong evidence in such cases cannot be judged to be a gap in health
economic evidence. One has to bear in mind that the goal of deci-
sion analysis is to make the best decision on the evidence available.
In conclusion, in this review, we identiﬁed limited evidence on
economic evaluations for CS. There is a huge lack of high-quality
studies, caused by either economic evaluation methodology or low
clinical evidence. Furthermore, there is a lack of studies validating
the published results, as higher evidence levels require reproduc-
ibility. But also, if the evidence level of the analyses is disregarded,
comparisons between alternative strategies are missing. These are
comparisons between ‘CAS’ and ‘BMT’ for the treatment of CS and
between ‘US combined with MRA supplemented with AG’ and ‘US
combinedwith CTA’ for the pre-endarterectomy imaging technique.
Furthermore, there is a gap in subgroup analyses, especially
according to factors such as gender, age or chronic diseases such as
hypertension, diabetes, ischaemic heart disease or cerebrovascular
diseases. There is also missing evidence concerning countries
outside the United States of America, as it is well known that the
results of economic evaluations depend on the setting, including the
health systemand the country.3We recommendﬁlling these gaps in
economic evidence. In the long run, this may lead to the more efﬁ-
cient use of available resources.
Appendix
The detailed search algorithm, as applied for both PubMed and
Google Scholar, is as follows:
‘carotid artery stenosis’ OR ‘carotid angioplasty’ OR ‘carotid
ultrasound’ OR ‘carotid endarterectomy’ OR ‘carotid artery stenting’
OR ‘magnetic resonance angiography’ OR ‘carotid stenosis’) AND
(‘cost-effectiveness’ OR ‘Markov model’ OR ‘costeutility’ OR ‘deci-
sion-analytic’ OR ‘costebeneﬁt’ OR ‘cost-effective’ OR ‘costs’ OR
‘cost comparison’ OR ‘economic impact’.
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